147 related articles for article (PubMed ID: 15174894)
1. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial.
Banerjee D; Honeybourne D; Khair OA
Treat Respir Med; 2004; 3(1):59-65. PubMed ID: 15174894
[TBL] [Abstract][Full Text] [Related]
2. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.
Banerjee D; Khair OA; Honeybourne D
Respir Med; 2005 Feb; 99(2):208-15. PubMed ID: 15715188
[TBL] [Abstract][Full Text] [Related]
3. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD.
Banerjee D; Khair OA; Honeybourne D
Eur Respir J; 2004 May; 23(5):685-91. PubMed ID: 15176680
[TBL] [Abstract][Full Text] [Related]
4. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data.
Basyigit I; Yildiz F; Ozkara SK; Yildirim E; Boyaci H; Ilgazli A
Ann Pharmacother; 2004 Sep; 38(9):1400-5. PubMed ID: 15252191
[TBL] [Abstract][Full Text] [Related]
5. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.
Siva R; Bafadhel M; Monteiro W; Brightling CE; Pavord ID
Int J Chron Obstruct Pulmon Dis; 2014; 9():179-86. PubMed ID: 24532969
[TBL] [Abstract][Full Text] [Related]
6. Clarithromycin targets neutrophilic airway inflammation in refractory asthma.
Simpson JL; Powell H; Boyle MJ; Scott RJ; Gibson PG
Am J Respir Crit Care Med; 2008 Jan; 177(2):148-55. PubMed ID: 17947611
[TBL] [Abstract][Full Text] [Related]
7. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial.
Simpson JL; Powell H; Baines KJ; Milne D; Coxson HO; Hansbro PM; Gibson PG
PLoS One; 2014; 9(8):e105609. PubMed ID: 25148049
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD.
Gompertz S; Stockley RA
Chest; 2002 Jul; 122(1):289-94. PubMed ID: 12114372
[TBL] [Abstract][Full Text] [Related]
9. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
10. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
Profita M; Chiappara G; Mirabella F; Di Giorgi R; Chimenti L; Costanzo G; Riccobono L; Bellia V; Bousquet J; Vignola AM
Thorax; 2003 Jul; 58(7):573-9. PubMed ID: 12832668
[TBL] [Abstract][Full Text] [Related]
11. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD.
Lapperre TS; Willems LN; Timens W; Rabe KF; Hiemstra PS; Postma DS; Sterk PJ
Chest; 2007 Jan; 131(1):53-9. PubMed ID: 17218556
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
13. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study.
Ordoñez CL; Stulbarg M; Grundland H; Liu JT; Boushey HA
Pediatr Pulmonol; 2001 Jul; 32(1):29-37. PubMed ID: 11416873
[TBL] [Abstract][Full Text] [Related]
14. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
[TBL] [Abstract][Full Text] [Related]
16. Impaired neutrophil chemotaxis in chronic obstructive pulmonary disease.
Yoshikawa T; Dent G; Ward J; Angco G; Nong G; Nomura N; Hirata K; Djukanovic R
Am J Respir Crit Care Med; 2007 Mar; 175(5):473-9. PubMed ID: 17110644
[TBL] [Abstract][Full Text] [Related]
17. [Changes of leukotriene B4 in induced sputum and plasma of patients with chronic obstructive pulmonary disease and the effects of theophylline].
Ding YL; Yao WZ; Liu Z; Wang YZ
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Jul; 28(7):441-4. PubMed ID: 16115390
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD.
Maneechotesuwan K; Wongkajornsilp A; Adcock IM; Barnes PJ
Chest; 2015 Nov; 148(5):1164-76. PubMed ID: 26043025
[TBL] [Abstract][Full Text] [Related]
19. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8.
Woolhouse IS; Bayley DL; Stockley RA
Thorax; 2002 Aug; 57(8):709-14. PubMed ID: 12149532
[TBL] [Abstract][Full Text] [Related]
20. Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial.
Prins HJ; Daniels JM; Lindeman JH; Lutter R; Boersma WG
Respir Med; 2016 Jan; 110():46-52. PubMed ID: 26616678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
